Artiva Biotherapeutics (ARTV) Operating Expenses (2023 - 2026)

Artiva Biotherapeutics (ARTV) has 4 years of Operating Expenses data on file, last reported at $24.4 million in Q1 2026.

• On a quarterly basis, Operating Expenses rose 10.19% year-over-year to $24.4 million in Q1 2026; TTM through Mar 2026 was $92.1 million, a 22.82% increase from a year earlier, with the FY2025 full-year figure at $89.8 million, up 32.99% from the prior year.
• Operating Expenses for Q1 2026 stood at $24.4 million, up from $21.9 million in the prior quarter.
• Over the last five years, Operating Expenses for ARTV reached as high as $24.4 million in Q1 2026 and fell as low as $14.3 million in Q4 2023.
• Historically, Operating Expenses has averaged $18.9 million across 4 years, with a median of $18.3 million in 2024.
• Across the five-year window, Operating Expenses rose 5.67% in 2024 and surged 50.38% in 2025, its largest moves.
• Year by year, Operating Expenses stood at $14.3 million in 2023, then climbed by 27.56% to $18.3 million in 2024, then grew by 20.06% to $21.9 million in 2025, then climbed by 11.39% to $24.4 million in 2026.
• Per Business Quant data, the three most recent Operating Expenses figures were $24.4 million in Q1 2026, $21.9 million in Q4 2025, and $22.9 million in Q3 2025.